REVIEW ARTIKEL : ADVERSE DRUG EVENTS ARIPIPRAZOLE PADA PASIEN DENGAN GEJALA PSIKOSIS

TANTIE NOER APRILIYA

Abstrak


Psikosis merupakan gangguan mental ditandai dengan adanya halusinasi, delusi, perilaku katatonik, perilaku kacau, berbicara kacau dan umumnya disertai dengan kinerja yang buruk. Antipsikotik digunakan untuk mengatasi psikosis dibagi menjadi antipsikotik generasi pertama dan kedua. Kedua generasi antipsikotik memiliki aktivitas farmakologi yang sama, yaitu memblokir reseptor dopamin D2. Efek samping ekstrapiramidal antipsikotik generasi kedua diketahui lebih rendah dibandingkan antipsikotik generasi pertama. Aripiprazole adalah obat antipsikotik generasi kedua golongan kuinolinon dengan mekanisme kerja yang unik di antara antipsikotik generasi kedua lainnya karena merupakan agonis parsial pada reseptor D2 dan 5HT-1a dan antagonis pada 5HT-2a. Penulisan review artikel ini bertujuan untuk mengumpulkan data terkait adverse drug events (ADE) aripiprazole berdasarkan uji klinis pada pasien dengan gejala psikosis. Pencarian sumber dilakukan secara elektronik melalui situs PubMed dengan menggunakan kata kunci “Adverse drug event” dan “Aripiprazole” didapatkan 307 artikel, sebanyak 12 artikel diantaranya memenuhi kriteria penulisan. ADE yang terjadi pada penggunaan aripiprazole diantaranya gangguan sistem saraf pusat, gangguan gastrointestinal, gangguan metabolisme, gangguan tidur, gangguan pergerakan otot, gangguan ritme jantung, dan gangguan insulin, dimana kejadian efek ekstrapiramidal berupa akathisia merupakan ADE yang paling sering terjadi.

Kata kunci: Aripiprazole, adverse drug events, antipsikosis, psikosis.


Teks Lengkap:

PDF

Referensi


Arciniegas, D. B. (2015). Psychosis. In CONTINUUM Lifelong Learning in Neurology (Vol. 21, Issue 3, pp. 715–736). Lippincott Williams and Wilkins. https://doi.org/10.1212/01.CON.0000466662.89908.e7

Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics, 302(1), 381–389. https://doi.org/10.1124/jpet.102.033175

Citrome, L., Ota, A., Nagamizu, K., Perry, P., Weiller, E., & Baker, R. A. (2016). The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: Results from a randomized, exploratory study. International Clinical Psychopharmacology, 31(4), 192–201. https://doi.org/10.1097/YIC.0000000000000123

Coffin, P. O., Santos, G. M., Das, M., Santos, D. M., Huffaker, S., Matheson, T., Gasper, J., Vittinghoff, E., & Colfax, G. N. (2013). Aripiprazole for the treatment of methamphetamine dependence: A randomized, double-blind, placebo-controlled trial. Addiction, 108(4), 751–761. https://doi.org/10.1111/add.12073

Fick, D. M., Semla, T. P., Steinman, M., Beizer, J., Brandt, N., Dombrowski, R., DuBeau, C. E., Pezzullo, L., Epplin, J. J., Flanagan, N., Morden, E., Hanlon, J., Hollmann, P., Laird, R., Linnebur, S., & Sandhu, S. (2019). American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society, 67(4), 674–694. https://doi.org/10.1111/jgs.15767

Gardner, D. M., Baldessarini, R. J., & Waraich, P. (2005). Modern antipsychotic drugs: A critical overview. In CMAJ (Vol. 172, Issue 13, pp. 1703–1711). Canadian Medical Association. https://doi.org/10.1503/cmaj.1041064

Haddad, P. M., & Correll, C. U. (2018). The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses. Therapeutic Advances in Psychopharmacology, 8(11), 303–318. https://doi.org/10.1177/2045125318781475

Harrison, T. S., & Perry, C. M. (2004). Aripiprazole: A Review of its Use in Schizophrenia and Schizoaffective Disorder. Drugs, 64(15), 1715–1736. https://doi.org/10.2165/00003495-200464150-00010

Jakobsen, K. D., Bruhn, C. H., Pagsberg, A. K., Fink-Jensen, A., & Nielsen, J. (2016). Neurological, metabolic, and psychiatric adverse events in children and adolescents treated with aripiprazole. Journal of Clinical Psychopharmacology, 36(5), 496–499. https://doi.org/10.1097/JCP.0000000000000548

Jennings, A. A., Guerin, N., & Foley, T. (2018). Development of a tool for monitoring the prescribing of antipsychotic medications to people with dementia in general practice: a modified eDelphi consensus study. Clinical Interventions in Aging, 13, 2107–2117. https://doi.org/10.2147/CIA.S178216

Jensen, K. G., Gärtner, S., Correll, C. U., Rudå, D., Klauber, D. G., Stentebjerg-Olesen, M., Fagerlund, B., Jepsen, J. R., Fink-Jensen, A., Juul, K., & Pagsberg, A. K. (2018). Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial. Psychopharmacology, 235(3), 681–693. https://doi.org/10.1007/s00213-017-4784-5

Juncal-Ruiz, M., Ramirez-Bonilla, M., Gomez-Arnau, J., Ortiz-Garcia de la Foz, V., Suarez-Pinilla, P., Martinez-Garcia, O., Neergaard, K. D., Tabares-Seisdedos, R., & Crespo-Facorro, B. (2017). Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment. Psychopharmacology, 234(17), 2563–2570. https://doi.org/10.1007/s00213-017-4646-1

Kamijima, K., Higuchi, T., Ishigooka, J., Ohmori, T., Ozaki, N., Kanba, S., Kinoshita, T., & Koyama, T. (2013). Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study). Journal of Affective Disorders, 151(3), 899–905. https://doi.org/10.1016/j.jad.2013.07.035

Kamijima, K., Kimura, M., Kuwahara, K., Kitayama, Y., & Tadori, Y. (2018). Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder. Psychiatry and Clinical Neurosciences, 72(8), 591–601. https://doi.org/10.1111/pcn.12663

Kozłowska, E., & Wysokiński, A. (2017). Severe weight gain after 4-year treatment with aripiprazole in a young man with schizophrenia. Archives of Psychiatry and Psychotherapy, 1, 13–15. https://doi.org/10.12740/APP/68727

Monti, J., Torterolo, P., & Pandi-Perumal, S. R. (2016). The effect of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep Medicine Reviews, 33. https://doi.org/10.1016/j.smrv.2016.05.002

Nicol, G. E., Yingling, M. D., Flavin, K. S., Schweiger, J. A., Patterson, B. W., Schechtman, K. B., & Newcomer, J. W. (2018). Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths a randomized clinical trial. JAMA Psychiatry, 75(8), 788–796. https://doi.org/10.1001/jamapsychiatry.2018.1088

Oommen M.B.B.S., E., Chand, Prabhat K. M.D., D. N. B., & Sharma, P.S.V.N, D.P.M., M. D. (n.d.). Aripiprazole-Induced Tardive Dystonia. https://doi.org/10.4088/pcc.v08n0611c

Pagsberg, A. K., Jeppesen, P., Klauber, D. G., Jensen, K. G., Rudå, D., Stentebjerg-Olesen, M., Jantzen, P., Rasmussen, S., Saldeen, E. A. S., Lauritsen, M. B. G., Bilenberg, N., Stenstrøm, A. D., Nyvang, L., Madsen, S., Werge, T. M., Lange, T., Gluud, C., Skoog, M., Winkel, P., … Fink-Jensen, A. (2017). Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. The Lancet Psychiatry, 4(8), 605–618. https://doi.org/10.1016/S2215-0366(17)30166-9

Potkin, S. G., Raoufinia, A., Mallikaarjun, S., Bricmont, P., Peters-Strickland, T., Kasper, W., Baker, R. A., Eramo, A., Sanchez, R., & McQuade, R. (2013). Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Current Medical Research and Opinion, 29(10), 1241–1251. https://doi.org/10.1185/03007995.2013.821973

Stefanova, I., Prissadova, N., Topolov, M., Getova, D., Badakov, H., & Kristev, A. (2015). Effects of Aripiprazol On Cholinergic Neurotransmission in Gastric Smooth Muscles. European Psychiatry, 30, 831. https://doi.org/10.1016/s0924-9338(15)30649-0

Takekita, Y., Fabbri, C., Kato, M., Nonen, S., Sakai, S., Sunada, N., Koshikawa, Y., Wakeno, M., Okugawa, G., Kinoshita, T., & Serretti, A. (2015). Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. European Archives of Psychiatry and Clinical Neuroscience, 265(7), 579–588. https://doi.org/10.1007/s00406-015-0605-1

Takekita, Y., Kato, M., Wakeno, M., Sakai, S., Suwa, A., Nishida, K., Okugawa, G., & Kinoshita, T. (2013). A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 40(1), 110–114. https://doi.org/10.1016/j.pnpbp.2012.09.010

Teff, K. L., Rickels, M. R., Grudziak, J., Fuller, C., Nguyen, H. L., & Rickels, K. (2013). Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes, 62(9), 3232–3240. https://doi.org/10.2337/db13-0430

Tuplin, E. W., & Holahan, M. R. (2017). Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Current Neuropharmacology, 15(8), 1192. https://doi.org/10.2174/1570159x15666170413115754

Wichniak, A., Wierzbicka, A., Walęcka, M., & Jernajczyk, W. (2017). Effects of Antidepressants on Sleep. Current Psychiatry Reports, 19(9), 1–7. https://doi.org/10.1007/s11920-017-0816-4

Yatham, L. N., Fountoulakis, K. N., Rahman, Z., Ammerman, D., Fyans, P., Marler, S. V., Baker, R. A., & Carlson, B. X. (2013). Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar i patients stratified by index manic or mixed episode. Journal of Affective Disorders, 147(1–3), 365–372. https://doi.org/10.1016/j.jad.2012.11.042




DOI: https://doi.org/10.24198/farmaka.v21i1.42695

DOI (PDF): https://doi.org/10.24198/farmaka.v21i1.42695.g19752

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved